News | June 16, 2014

Boston Scientific Initiates RESPOND Post Market Registry for Lotus Valve System

June 16, 2014 — Boston Scientific Corp. has initiated the RESPOND post-market registry to assess real-world performance of the Lotus valve system. The RESPOND registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world.

Three patients enrolled in the RESPOND registry thus far have been successfully implanted with the Lotus system. Nicolas Van Mieghem, M.D., and Peter De Jaegere, M.D., Ph.D., led the first transcatheter aortic valve implantation (TAVI) procedure at Erasmus Medical Center in Rotterdam, the Netherlands, using the Boston Scientific Safari pre-shaped TAVI guidewire, which received U.S. Food and Drug Administration (FDA) clearance and CE mark in 2013 and is designed to facilitate stable, atraumatic valve placement.

The RESPOND registry is a prospective, open label, single-arm, multicenter, observational post-market study. Clinical follow-up is at discharge, 30 days, 12 months and annually through five years. It features a primary endpoint of all-cause mortality compared to a performance goal, plus secondary endpoints using Valve Academic Research Consortium guidelines and definitions. An independent core laboratory will analyze the echocardiographic images, and an independent clinical events committee will adjudicate key clinical events. These measures are designed to increase the quality of the collected data and address inconsistencies with site-reported data commonly observed in post market studies.

"It's a great privilege to kick off the RESPOND registry with this first implant," said Van Mieghem, co-lead principal investigator. "The Lotus valve system truly is an elegant and novel transcatheter valve concept providing a high level of precision and control. It simplifies the TAVI procedure by having the ability to assess valve functionality fully before release, which helps ensure optimal valve placement and a positive clinical outcome."

The Lotus valve offers a unique and effective treatment for patients with severe aortic stenosis at high risk of surgical valve replacement. It is a next-generation TAVI device designed to give physicians total control throughout the TAVI procedure.

"The Lotus valve system functions early and allows for precise valve placement without the need for temporary pacing during deployment," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "Differentiated features include an Adaptive Seal that minimizes paravalvular leakage, which was confirmed in the results of the REPRISE clinical program."

REPRISE II six-month outcomes were presented at EuroPCR 2014 in Paris. The clinical study demonstrated that the Lotus valve system delivered sustained safety and effectiveness outcomes out to six months, with only 1.1 percent of patients having moderate paravalvular aortic regurgitation (leaking). No severe cases occurred. REPRISE II is evaluating the Lotus valve system in symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement.

For more information: www.bostonscientific.com

Related Content

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
Overlay Init